Chronic hepatitis D

Abstract

Aim. The present review was designed to summarize the current views of the main characteristics of hepatitis D virus (HDV), the prevalence of this pathology, and prospects for the treatment of chronic HDV infection. Conceptual issues. It is believed that around 15 million people all over the world are infected with hepatitis D virus; this figure amounts to approximately 15% of all the patients presenting with hepatitis B (HBV). Russia ranks among the countries with a high prevalence of HDV infection. The patients with chronic hepatitis D are characterized by a more severe clinical course of the disease, faster development of liver cirrhosis, higher risks of hepatocellular carcinoma, and more frequent decompensation of liver cirrhosis in comparison with the patients presenting with chronic hepatitis B in the absence of the D-agent. Conclusion. Interferon-alpha (IFN-a) thus far remains the sole officially approved medication with antiviral properties for the treatment of chronic hepatitis D infection. The effectiveness of IFN-a therapy does not exceed 20-25%. At present, Myrcludex B and Lonafarnib are considered to provide a promising tool for the management of chronic hepatitis D infection.